Pod Insights Pharmacy Podcast Network Bup Basics: Buprenorphine for Pain Management | Geriatric Pharmacy Focus About this episode Dr. Tamara Ruggles: www.linkedin.com/in/tamara-ruggles-491882251 Dr. Sing Ping Show: https://www.linkedin.com/in/sing-ping-chow-pharm-d-bcps-497365175/ Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion: https://pubmed.ncbi.nlm.nih.gov/31917418/
Transcript 0:02 Speaker 00 Feeling lost with the complexities of pharmacy accounting?
0:05 Speaker 01 In pharmacy today, there's so many different variables and issues that impact the pharmacy books, records, accounting, the profitability of the store, so forth. There's different components of pharmacy that have its own nuances from an accounting standpoint. And so it's tricky. There's no doubt about it.
0:23 Speaker 00 Ready to take your pharmacy to the next level but don't know where to start? Sykes and Company is here to help. Introducing the RX Assessment. With the RX Assessment, the pharmacy CPAs and advisors at Sykes will do a deep dive into your accounting and tax situation and give you the action steps you need to take to take your pharmacy to the next level.
0:44 Speaker 01 If you're interested in, you know, working with a team who understands the industry and how the accounting and tax should really be in a pharmacy, this is, this is your chance to get a under the hood check of what's going on and getting the feedback of any issues or concerns or again, things we think you're doing really well.
1:02 Speaker 00 Get the financial checkup your pharmacy needs and head over to Sykes-CPA.com or call 252-482-7644.
1:32 Speaker 02 Thanks for listening to the Pharmacy Podcast Network.
1:50 Speaker 02 We have an aging population taking more medications than ever before. On this podcast, I will interview experts in geriatric medicine to gain insight so we can provide optimal care to patients in their golden years. I'm your host, Dr. Tamara Ruggles, and this is the Geriatric Pharmacy Focus.
2:09 Speaker 03 Hello listeners, welcome back to the Geriatric Pharmacy Focus. I am so excited today to have a wonderful guest, Dr. Sing Ping Chow, who if you follow him on LinkedIn, you know he produces some awesome content on pain management. And about a year and a half ago, I had Dr. Laura Meyer-Hunko on talking about opioid stewardship, and she briefly brought up the Butrans patch. And I had not seen that in my nursing home patients as a way to manage pain. And she kind of opened my eyes, I guess you could say, to the Butrans patch and buprenorphine in my nursing home patients for pain management, and kind of the benefits that that medication brings. So I've been looking more into it and then found Sing Ping on LinkedIn, who also produces awesome content on buprenorphine,
2:54 Speaker 03 and has kind of helped me with some of the guides he has put out. So if you're not following on LinkedIn, do that now. But he is a pain management specialist at the VA, at the Bay Pines VA in Florida. And so Sing Ping, welcome, and please tell us a little bit about yourself.
3:10 Speaker 04 Thank you. Thank you, Tamara. Thank you so much for introducing and inviting me to the podcast. I'm very excited. So my name is Sing Ping. I am an inpatient pain management pharmacist. So I just want to make a little disclaimer before I go into the podcast today. So everything that I'm mentioning today will be the opinion of my own, and it does not reflect any opinion to my employer. So with that, I want to say that my role, my current role has been rapidly evolving over the last two and a half years. So when I first started my position, I was having some sort of consult structure in place.
3:58 Speaker 04 And at the time, I was helping out physicians and patients who are really struggling with with their pain management. And so after some time doing more of a consult-based service, I realized that the reach was not enough. So at that time, I was like, I need to really get almost like deeper into the system and really see what is, how can I help even more? So after I, you know, realized that the consult service isn't getting as much traction, then I started doing table rounds with the hospitalist.
4:42 Speaker 04 And at that time, after I started doing that, I really gained more appreciation and understanding of the practice, really the granular practice and how they think about, how they think through pain management, how do they approach medication management and opioids? And after that, that really opens my eyes more because only when you understand how they practice, how they see opioid management, then you can actually address those root cause and provide the education. So that was my transition from consult to more of a table round with hospitalists.
5:26 Speaker 04 And then afterwards, I feel like I can do even more than just rounding with hospitalists. And now I am transitioning more to doing opioid stewardship and really looking at like a systemic level in the internal medicine wards and how can I address the IV opioid use and how can I really optimize the opioids and non-opioids for patients for better care? So it's been rapidly evolving just in the last two and a half years, and I'm very excited to do what I'm doing because there are the directions and. The potentials and possibilities are limitless.
6:11 Speaker 04 So if I can share three things that makes us important and really why we're such an integral part to the healthcare system and how we can really address the current opioid crisis in the current landscape in America. I would say the first thing is that many of us can recognize the opioid dose. But not many of us, let it be clinicians or pharmacists, will be able to comment or clinically evaluate a dose. And what I mean by that is when I percept pharmacy resident or medical resident, I love asking them this question.
6:55 Speaker 04 How would you comment a certain opioid dose? And I love using oxycodone thirty milligrams because that's kind of like moderate to a high dose as a single thirty milligram dose. But I wanna see what kind of rationale or what kind of reasoning do they have to when I ask them to comment on it? And so for the most part, I would get answers like, I'm not sure. And when I do get answers like, okay, yeah, you know, it's a high dose or a medium dose. And then when I dig deeper and when I ask them, why do you think it's medium or high? And then the rationale is usually, oh, because that's what I'm being taught.
7:40 Speaker 04 And what I was really hoping for was, you know, they can really share more insights about, oh, because that's the conversion or because, you know, because of this pharmacokinetic or dynamic or more of an in-depth rationale of that. But unfortunately, that's not what I see. And that brings me to the second point that why it's so important to have us, you know, be part of the team. Because with the current education system, let it be medical school or pharmacy school, I don't think that the Education is enough to, we're not giving enough training to allow physicians or pharmacists
8:25 Speaker 04 to, like I say, clinically evaluate the opioid dose. Because I think for the most part from what I hear is that most students and residents, they only get maybe like a week of training and that's it, like a week of lecture, but what, what really is one week of lecture, right? And what we're dealing with is really, you know, with, with the opioid pandemic and opioid crisis, we're looking at high opioid doses and really sophisticated opioid doses that sometimes it's, you know, where it's kind of unquestionable practice, right? And so we need almost like a sharper eyes to address those problems.
9:05 Speaker 04 But with that little training, I don't think that's enough. So that's kind of what we're, kind of where, where we're at, unfortunately. And so, and the third thing that I want to share as to why I think we are, why we're crucial in the current healthcare system, kind of looking ahead with everything going on with AI, right? Cause there's a lot of buzz with AI currently and, and how AI can be really integral in a lot of healthcare areas. So I like to think that I do not think that AI will likely replace pain management
9:47 Speaker 04 or palliative care pharmacists, because humans are very, we're very social animals. We want that human attention. We crave for that human, human interaction. So until the point where AI or technology is so sophisticated to a point that it can almost replace, you know, the human interaction like 100%, I don't think that we're, we will be replaceable. And even, I would say, even at a point where the, because I've seen news about the humanoids and, and did something down the pipeline, right? Even when the time where
10:27 Speaker 04 Where the A I, the A I technology is so sophisticated that, you know, it becomes the mainstream. That means that the real human to human interaction provided by pain management pharmacists is even going to be so rare. And the world operates with scarcity. So I think that there is always going to be a role for us because that human interaction, I don't think is replaceable. So with that, I think our role is so crucial. Our job is likely going to be evergreen, at least for the next ten to fifteen years. So that's us and that's me.
11:02 Speaker 03 Yeah, yeah, it's a good day to be a pain management pharmacist. And I agree with so many things you said. Um, yeah, I don't really remember. I don't remember how long our pain management, you know, lectures were in pharmacy school, but I know I still have a lot to learn, especially in regards to buprenorphine. I don't really remember learning about it that much. Um, it's been recently, I've been learning more and more about it. But and you mentioned the relationships and joining the roundtables. And that's huge because if you develop a relationship with the provider where they can trust you, then they're really going to be willing to reach out to you, get recommendations, ask for that consult. So huge. So let's get into buprenorphine. I'm so curious what you are going to teach us today.
11:45 Speaker 03 Um, first of all, can you give us a bit of an overview mechanism of action? Um, yeah, just a little bit of overview of buprenorphine.
11:54 Speaker 04 Absolutely. So there's so many things about buprenorphine. I feel like, you know, sometimes I like to joke about it. I can talk of it for hours. But if there are some high level highlights about buprenorphine, let's, let's start with this, this fact. Okay, so because so many of us would confuse with buprenorphine, it's the same as Suboxone. And that's false. And, and I hear it all the time, right? And so when, when a patient is on buprenorphine, then either pharmacists or physicians, they would say, oh, the patient is on Suboxone. But they're two different things. I like to think about using this analogy is that like all apples are fruit, but not all fruits are. Apples.
12:38 Speaker 04 So we can think about that the buprenorphine is the fruit. It's more inclusive. While the suboxone is only one type of fruit, which is apple or grapes or whatever you want to think about it. So that's very important because with buprenorphine, there's so many formulations. There's so many dosage form. So I like to call it just buprenorphine, just for simplistic purpose. So that's very key. So when it comes to explaining buprenorphine, I like to, I think there are two major audience to explain it to. The first group is the patients and the second group would be the physicians and clinicians.
13:21 Speaker 04 So the reason why I think it's very important, because in the end of the day, we want to get that ideas across to patients. We want to let patients know in the most simplistic and understandable way. So then they can have buy in. And unfortunately, what, at least what I've been taught in, in, in some C E's or, you know, talking to colleagues, sometimes we would say, oh, we have to emphasize that, to emphasize that this to patients that buprenorphine is a partial mu agonist so that it works better. And, and to me, I think that's false. Because at what life circumstances do we even use the word agonist in life? Unless, unless, yeah, right?
14:04 Speaker 04 Unless you are nerd or you have a very fancy, very deep chemistry background, then maybe you would use the word agonist in your life. So when it comes to explaining buprenorphine to patients, I try not to even use the word partial mu agonist. Because all that the patient can register is the word partial. And they're not going to have any context with, let it be mu or agonist, they're not going to know. So what happens if you tell a patient that it's a partial mu agonist? Then all that their mind will be anchoring to is the word partial. And that means you have to almost spend extra time to explain
14:49 Speaker 04 and kind of go back to the drawing board, telling them, oh, it's not really partial. It is still a very potent and great medication. I feel like that is almost setting up yourself for failure.
15:01 Speaker 04 So when I do explain it to patients now, I feel like after failing it so many times, when I I used to do that myself as well, and after getting so many googly eyes, I I'm like, no, let's just not tell them it's a partial muaginist. I would just say it's a opioid that works differently than the conventional opioids. It is still a very potent and strong opioid. It's just that it works differently. And then that way, it's way easier for them to digest when they just hear the most simplistic form. Now, the other thing that I think it's also beneficial for patients to understand buprenorphine is that buprenorphine is such a hard word to pronounce.
15:45 Speaker 04 I don't know if you find it as well. And I just call it bup. I tell patients that, hey, it's a it's a medication called buprenorphine, but for simplistic purpose, you can call it bup, and we will understand. And I know that for some of my colleagues, we call it bup as well. Because I think that when we are able to associate, when we can, when we can say that name, then it's easier for the patient to be adhering to the medication. It's easier for them to, you know, know and understand that medication. So I think that's very important. So that's everything about patient side. And then, you know, with the clinician, you know, explaining to clinician, now we can
16:29 Speaker 04 actually use the word, it's a partial muaginist. So one of, and before I even dig deep into, you know, the partial muaginist and the mechanism, there's one very good resource I want to share with you. It's a paper by Dr. Lynn Webster. It's published in 2020. If you type his name, L Y N N W E B S T E R, Dr. Lynn Webster, and type buprenorphine, that paper would came, that paper would come out. And it's such a good paper. It's a very good overview of everything buprenorphine, and I highly recommend that. I share it to residents, students, because it's a very good resource.
17:14 Speaker 04 So one of the biggest misconceptions with buprenorphine and being a partial mu agonist is that it is partial, it's less effective. But that's, again, that's not true. Because when we think about, you know, the potency of an opioid, it has more to do than just the fact that it's a partial mu agonist. So what really, when we think about partial mu agonist, is that when the researchers look at buprenorphine and compare it to like a full mu opioid, for example, let it be morphine or oxycodone. So those are all done in vitro.
17:58 Speaker 04 And so it, it, it, yes, it, it does show that it's partial, it does not induce as much of an effect in vitro. But when it comes to potency, there's more than just a full mu or partial mu, because the, there's also a lot to do with how much it binds the receptor, the affinity, and how long it stays there. So with buprenorphine, it's very interesting because buprenorphine has very, very high affinity to the mu receptors, and it also lingers, it sticks to the receptors for a long time. That's what, it's part of the package that makes buprenorphine a very, very potent opioid
18:41 Speaker 04 compared to, let it be morphine or oxycodone. So it's very important not to think that just because we are, you know, just because buprenorphine is a partial mu agonist, there isn't anything partial about that. So that's very key. Now, the potency with buprenorphine on research, sometimes there are some mention about it being about 20 to 50 times more potent compared to morphine, and there are some mention that it can be as potent as 100 times than morphine. And if I give you more context, Tamara, that fentanyl is 100 times more potent.
19:24 Speaker 04 Potent than morphine. So that means if we take the upper limit of the potency of buprenorphine, which is one hundred times. I know some people would disagree because it's more so like twenty to fifty, but if we take the upper limit, that means that it can potentially be as potent as fentanyl. And we can talk more about the, you know, conversion later, but that's why, you know, with buprenorphine, it's really not partial. It's quite potent if we look at how you know, potent it is compared to morphine and how it's relative to fentanyl. One last thing I want to mention about buprenorphine is that it has what we call a kappa antagonistic property.
20:08 Speaker 04 And so this is very interesting because we know that when patients are on chronic opioid, they are, there's more association with depression and that's very well studied and from anecdotal experience as well is that when patients are on chronic opioid therapy, a lot of times there is depression and other mood disorder really induced by, by the full meal opioid. Now, there are actually studies that look into buprenorphine because of that kappa antagonistic property. It actually can lessen, it, it almost helps with the depression. So in our practice, when I work with the physician in the outpatient setting,
20:53 Speaker 04 what we saw anecdotally is that when patient transitioned to, from full meal opioid to buprenorphine, sometimes the patient will have better mood and their energy is better. And because really of that, maybe it's, there, there has to be something to do with that kappa antagonistic property. So there's a lot of interesting facts about buprenorphine. That's why it's such an exciting drug.
21:20 Speaker 03 Yeah, I love learning about it and especially the benefits. And if you can, you know, switch a medication that would improve a patient's mood, potentially reduce polypharmacy with the need for an antidepressant. That's a win for sure. So you've talked about one benefit of Bup.
21:37 Speaker 04 Yes.
21:38 Speaker 03 Let's talk about some of the other benefits of using it over other opioids.
21:44 Speaker 04 Absolutely. So with buprenorphine, there are a couple of interesting benefits, or we can think of it as almost like a less side effects, because I like to think less side effects is still a win. So the first thing with buprenorphine is that there is almost like a less testosterone drop, even though that testosterone, kind of less effect to the testosterone. It's really from small studies back in, back in early 2000. So in that study, they looked at suboxone, which is a, you know, a dose that is usually for patients with opioid use disorder
22:29 Speaker 04 or dependence and sometimes complex pain. And in that study, they look at suboxone compared to methadone. So what they saw is that there is a statistical difference in terms of testosterone decrease. So, and with that, the buprenorphine group has less testosterone drop than methadone, meaning that methadone is going to cause more testosterone drop. Now, the other aspect of that is that they, in that study, they also look into libido. And, oh, that, that, you know, difference is quite significant. So they saw that in the, about 20% of the patients in,
23:11 Speaker 04 in the buprenorphine group, there is, there is a decrease and, and influence of the libido. And in the methadone group, there is almost like 80% or something like that. So the difference is huge. Now, with that caveat is that, because this study, they're really looking at buprenorphine in a higher dose, because when we look at the buprenorphine that comes in less, you know, in, in lower dose like Butrin and Belbuka, it's. I would say it's kind of hard to translate that to like a lower dose buprenorphine product. So take it with a grain of salt. So there is definitely some studies out there to look into the testosterone influence.
23:55 Speaker 04 But again, you know, there's some caveat in there in terms of what patient population group they study at and also the dosing, because dosing is everything when it comes to opioid management. Now, there are also two big other side effects that buprenorphine has less of an effect compared to the full meal opioid or the conventional opioid. So the first one is constipation. I love talking about constipation with patients because you know what, Tamara? A lot of patients feel that talk about poop or talk about bowel movement is so embarrassing. I don't know why.
24:34 Speaker 04 Uh, yeah. And so sometimes, and just from my experience, is that patients don't talk about it until things are, you know, hitting the roof. It's like day four, they're not having a bowel movement and, and, and something is going south and they tell me. So it's very important that you keep track. So I like to tell patients that I'm not a bowel movement police. One to three days, I'm good because uh, again, you know, just like pain management with constipation, there's also some subjectivity, uh, subjectivity with that. It has to do with their subjective feeling of whether or not they feel backed up. And so there's some subjective factors in there.
25:16 Speaker 04 And everyone has their own bowel movement pattern, so everyone's different. But I like to just keep it very broad in general. I tell them, you know, one to three days, I'm good. Four days, you gotta be more watchful. And five days, probably we gotta do something. So it's important to kind of gauge the baseline and then, you know, let them know kind of what kind of ballpark that I'm looking for. So with buprenorphine, there are studies that look at. That looked at the incidence of constipation and they compared that with morphine. So what they found is that buprenorphine is associated with less constipation.
25:57 Speaker 04 And perhaps there is some mechanistic explanation to that if we want to get to more of a biochemical reasoning of that is that there is some, there is a mechanism called the beta arrestin. And this is a very interesting mechanism. Once the opioid binds to the mu receptor, there is this part of a cascade or a cellular response called the beta arrestin. And this beta arrestin is, is proposed to be doing the, you know, that has to do with a lot of the side effects with the opioids. So part of that is the constipation and the other part is also the respiratory depression.
26:40 Speaker 04 So all that is, has to do with the beta arrestin. And because of the very fact that buprenorphine is a partial mu agonist, so what, what scientists are postulating is that the, because of almost like a less, almost like a partial effect, that it doesn't have as much of an effect to this side effect cascade dictated by the beta arrestin. That's why, maybe that's why we're seeing less of a constipation side effects from buprenorphine. Now, there is the last one that is why buprenorphine is being more and more, you know, promoted
27:22 Speaker 04 in nowadays landscape is really because of the fact that it has way less respiratory depression compared to the full mu opioid. So this one has to do with what we call the ceiling effect of the buprenorphine. We saw, we, and it's again, it's due to the partial, at the partial mu agonist effect that there is a ceiling effect that has to do, that comes with it. So what we mean by ceiling effect is that after a certain dose of buprenorphine, the Then it almost like plateaus out. So the more buprenorphine you give, it's not going to cause more respiratory depression.
28:05 Speaker 04 Now, there's one catch to that because I don't want everyone to almost like go go on, you know, to to feeling to almost too safe with buprenorphine. Because there is one caveat with that is when patients are on buprenorphine with, for example, like a benzodiazepine, it can, like in that combination itself, can also cause that, you know, respiratory depression. And there is actually a study that looked into the the overdose death reports. And when they look at patients who are overdose on purely buprenorphine, the incidence is very, very low. But when they look at patients who are on buprenorphine,
28:49 Speaker 04 but they also found other, you know, sedatives like benzodiazepine or other sedatives in there, that's where they saw like a almost like a substantial increase with the overdose in those cases. So that's why it's very important that just because buprenorphine, yes, let's acknowledge that it has a safer, you know, scientific profile, let it be constipation or the respiratory depression. But it's still very important to make sure that we are trying not to use as much of a benzodiazepine. If you do, make sure that they get the naloxone and be close monitoring. So that's very, very important.
29:29 Speaker 03 Yeah, I think that makes a lot of sense. And those are perks, especially when we're talking about our geriatrics. How many of them are already constipated before you put them on any sort of pain medication? And so we do have to be vigilant about, you know, being proactive, monitoring it, starting something. So I love that benefit of buprenorphine and especially, you know, the respiratory depression. Because our older adults maybe already have, you know, less reserve. They might have COPD, long-term asthma. And you know what? They're probably not exercising and taking a deep breath very often. And, you know, doing that kind of respiratory therapy or exercise. So those benefits are huge.
30:13 Speaker 03 And then remind me, with buprenorphine and kidney impairment, liver impairment, is there any precautions that need to be used there? Or can they, can buprenorphine be used for kidney and liver impairment?
30:24 Speaker 04 That is such a good question. It's almost like a million dollar question because, because you know what, like with buprenorphine, I want to say that when it first came out in the late 60s and almost in 70s, there's, you know, a lot of studies. When, when it first came out, it's, it's in the IV IM formulation. And then after, I would say probably in the 90s, where there's still a lot of research. And then there is almost like a gap period where it just almost like stopped. Like everything is about like opioid use disorder or dependence. And, and, and these studies on pain management is lacking.
31:07 Speaker 04 And so there is almost this, this period where we don't have a lot of data. And now we're slowly picking back up. But then we, now that we're slowly picking back up and then we don't, we were almost missing a lot of data in the interim. So I would say, that's such a good question. Because with the renal dysfunction and the hepatic dysfunction, there is more data in the hepatic dysfunction population. So what we saw is that even when we look at the drug label itself, it says that the, when patients have hepatic dysfunction
31:45 Speaker 04 in the very severe hepatic dysfunction group, there is almost like a 180% of serum level in AUC increase compared to healthy subjects. So in those patient population, we would recommend to, you know, going back to the first principle of opioid dosing is start low, go slow. And so that, I feel like with the hepatic dysfunction group, there's more data. But one of the very interesting caveat is that the, with buprenorphine, because it has so many formulation. One formulation that is actually recommend against in the hepatic dysfunction group is this obloxone.
32:28 Speaker 04 And so the buprenorphine in hepatic impairment, yes, we can start low, go slow. And do more monitoring, but specifically with Suboxone, what happens is that because Suboxone has both the buprenorphine and naloxone co-formulated in there. What happens is the problem isn't the buprenorphine. The problem is the naloxone because with hepatic impairment, the naloxone is really not cleared. So if you look at the drug label of Suboxone, it would really say recommend against, like, don't even use it because the problem being when the, when our body is not clearing the naloxone,
33:12 Speaker 04 then the fear, the concern is that they, they will be causing more withdrawal symptoms. It's almost like the, the naloxone is in the system for too long and it will almost like causing this constant antagonist effect while there is the buprenorphine in the system. So if we look into the patch insert, that is one formulation that it would be recommended against, and that is the Suboxone. And with the renal dysfunction, that group, wow, I, I want to say like there really isn't a lot of data. I recently published a paper with BELBUCA use in end-stage renal disease.
33:55 Speaker 04 It's a case report and I do that case report because I really want to tell people out there and really start looking at, start studying in this patient population group because we don't know as much. When we look at the up-to-date or LexiCom and go to the kidney impairment and see if there is any dose adjustment, they would say no adjustment. But I am a little bit partial and, and, and not quite sure about that because we know that with renal impairment, there is a active metabolite from buprenorphine. It's called norbuprenorphine. Norbuprenorphine is still considered active if we look into the literature
34:41 Speaker 04 and, and the renal impaired patients, that norbuprenorphine can still be accumulated.
34:49 Speaker 04 So now, is there a lot of studies and case report out there saying that buprenorphine should not be used in renal impaired patients? No, because if we look into, like if we do a PubMed search or Google Scholar search and search for renal impairment and buprenorphine, they actually, they actually recommend in some of the review articles, they recommend to use buprenorphine in renal impaired patients. But if we go to the very, if we go to the references, we saw that a lot of that is really referencing in, you know, small studies, case reports.
35:31 Speaker 04 So that's why in the renal patients, I feel like the data is not, not enough. But am I going to say that we should avoid using it? No, I think that we should start using it more, but in a more careful manner, so then we can start to gather more data. Because I feel like if we want, I feel like at this trend of the opioid prescribing landscape nowadays, I feel like the buprenorphine is going to get more and more popularity. And this is the time we want to really start thinking about and really start using it in those patients, so then we get an even more clear experience in what we're going
36:16 Speaker 04 to do in the renal impaired patients.
36:18 Speaker 03 Yeah, yeah, always with geriatrics, right? Start low, go slow.
36:23 Speaker 04 Absolutely.
36:24 Speaker 03 You can use the same.
36:25 Speaker 04 That's principle number one.
36:26 Speaker 03 You got it. So as we're talking about dosing, you know, that's one thing where I feel like is a gray area with buprenorphine. Can you just talk about dosing and conversions from other opioids to buprenorphine?
36:40 Speaker 04 Yeah, and I would say conversion and dosing is another area that is a little bit ambiguous, okay? And because again, the, with albuprenorphine works being a partial mu agonist, is that its conversion is not as straightforward as we think.
37:01 Speaker 04 Now, I like to think of the conversion of buprenorphine as there are two ways to think through that. There is a theoretical way and there is also a practical way. So let's just start with the theoretical way and kind of going back to the drawing board of how buprenorphine is about 20 to 50 times more potent than morphine and in some other cases in the upper limit, it can potentially be 100 times more potent than morphine. So with that in mind, I've seen some, you know, some dosing guides that would almost convert
37:39 Speaker 04 the buprenorphine, the butrin's patch, they convert the butrin's patch almost very, very similarly to the way we convert to the fentanyl patch. Maybe my postulation is that it's really due to that potency, you know, how buprenorphine can potentially be as potent as fentanyl. So I have seen that. Now, the, a lot of times I still go back to the dosing guide, there's a little table that is provided by the belbuca manufacturer, but there is some catch to that. I feel like there is, everything with the conversion is, is there, there's some sort of caveat to that.
38:22 Speaker 04 Because if we look at the, how we're going to convert patients who are on 90 to 160 oral morphine equivalent, they would recommend to convert them to 300 microgram twice a day belbuca. But if we think about 90 to 160 oral morphine equivalent, that's a huge jump, right? And so I would wish that if it's, for example, like 90 to maybe like 120, sure, but 90 to 160, then just from that range, you know that there, it's almost like, it's too imprecise to put our
39:02 Speaker 04 fingers on how to really convert from the fumiopioid to belbuca or butrin. Now, the practical side of it is really what, what it get, where it gets interesting.
39:17 Speaker 04 With buprenorphine, there is something that is quite unique to itself. It's that for some reason, it has to do with, again, the fact that it's a partial mu agonist, is that it can cause what we call precipitated withdrawal. And this is so interesting, that likely because it's a, you know, the intrinsic activity because of the partial mu agonist. So there is this phenomenon called the precipitated withdrawal. And so it happens when a patient has been on full mu opioid for some time, and sometimes if they're on high dose.
39:58 Speaker 04 And if we start them on a, you know, let it be like a suboxone 2mg or 4mg from the get-go, it can cause what we call precipitated withdrawal. And that's why there is more and more studies starting around, I would say, in the last 5 to 10 years. That's why people start to really promote this idea called micro induction. Have you heard of the micro induction so far? No. With buprenorphine? Yeah, yeah, it's a very interesting thing. So the idea of that is because now that we know if a patient is on this full mu opioid
40:39 Speaker 04 for some time, and then you start them on like a suboxone, which is the milligram dose, then it can cause that precipitated withdrawal. So the idea of the micro induction is that we want to sneak in, we slowly introduce that buprenorphine into the system with the hope that it's not going to cause that precipitated withdrawal. So that's what we call the micro induction. It's almost like, it's very sophisticated. It takes more time compared to, you know, a conventional conversion from like a full mu to like a suboxone.
41:20 Speaker 04 Those are, when we convert from full mu to suboxone, those cases are mostly for patients who have opioid use disorder, dependence, or we call it like a complex pain picture. Now... I do have patients where they're on just maybe like, you know, oxycodone, you know, 10 milligrams, you know, four times a day, or hydrocodone. And then when we convert them to, when we convert them to buprenorphine, let it be buprenorphine, what I would do is that I would start low and go slow because something to really bear in mind is this precipitated withdrawal side effects.
42:05 Speaker 04 It's kind of hard to predict. So with buprenorphine conversion, it's that, that's why I call it the practical side of it, is it's not as straightforward as going from one to another, like from morphine to with the lotus. It's, it doesn't quite operate like that. Now, the one last thing I want to really talk about with the conversion, right? Because when we think about conversion, one of its use with opioid conversion is to determine the PRN dosing of the opioid. Let's say, for example, someone is, you know, on certain amount of oromorphine equivalent, and then they break a hip. And then what do we do with that, you know, with that breakthrough pain, for example?
42:50 Speaker 04 Then we will start to think about, okay, we will, you know, tally up all the total daily oromorphine equivalent, and then do our 10 to 20%, you know, 10 to 20% of total daily dose, and then go from there, and then that's our PRN dose. But here's the thing, with suboxone, okay, which is the milligram dose of buprenorphine, we know that that's, doesn't quite apply. And the reason why is because when we really look at, if we kind of go back to the theoretical potency and conversion argument of buprenorphine, right?
43:32 Speaker 04 We know that it's about like 50, 20 to 50 times more potent than a full mu opioid. But if we, if we really use that conversion and, and look into How much um oromorphin equivalent with um like suboxone or buprenorphine in milligram dose? If we really do that math, theoretical math, it can come to maybe like hundreds of oromorphin equivalents. But when in practical setting, let's say someone is indeed on suboxone, let it be twelve, sixteen milligrams. And they do need to have um to undergo some sort of surgery.
44:13 Speaker 04 Do we do that ten to twenty percent, meaning that if they're on hundreds of theoretical oromorphin equivalent? Do we do we give them like one hundred, you know, or or fifty to a hundred per PRN dose? We don't do that because from my practice, anecdotally, I would start with oxycodone ten, maybe fifteen milligrams. Um when patients are on suboxone. So when we think about that, really, like, does that PRN ten to twenty percent apply to use the box on? We don't quite know. That's why there is still a lot of things we don't quite know. We can't really just use what we know about opioid conversion and directly apply to buprenorphine.
44:58 Speaker 04 Let it be the microgram dose or the milligram dose because the conversion is not as straightforward. And we also know that the PRN calculation doesn't quite reflect from what we have been doing with, let's say, the formula opioid so far.
45:15 Speaker 03 Yeah, I love buprenorphine for all the benefits. One of the negatives is certainly the dosing. Because every time I look it up, I'm like, oh, no, I gotta ask somebody because I I don't I don't know what I'm doing. But the great thing is you can start low and titrate up based on, you know, the patient's pain. So is it complicated? Yes, but you can. You can change the dose fairly quickly, right? Like, you don't have to let him be on that dose for too long before you can titrate up?
45:47 Speaker 04 Yeah, so on, if we think about like the buprenorphine, you know, there are multiple, there are multiple ways to, with different formulations, there are different dose increase strategy. So, yes, there, it would recommend, you know, you have to wait for a few days to increase. But if we think about the, I know this is really off-label and this is, again, it's anecdotal. Experience is that because buprenorphine, it does have a long half-life. And so we do really wanna let it sit in the system for some time before we increase.
46:26 Speaker 04 So that's one thing about buprenorphine and dose increase is that we don't wanna increase it too aggressively. Think of it, think about it almost like methadone, right? Because methadone, we know that it has a very, very long half-life. And if we increase it every day, that's where, you know, things can happen. But I would say, I would challenge that notion is that because we know that buprenorphine has a safer, the safer prophylactic profile. I would say that you can probably go more aggressive, you can increase it more often compared to, let's say, a methadone, methadone, we don't absolutely do not increase it unless it's five to seven days or sometimes even longer.
47:11 Speaker 04 But with buprenorphine, I think you can do it in a shorter amount of time.
47:16 Speaker 03 Yeah, I think I read three days is about, is that right? To titrate after about three days?
47:23 Speaker 04 Yeah, something like that. But something to, something to think about is that it really depends on your, on the setting where you're managing it. If it's outpatient, right? If it's outpatient, we have more grace to, you know, kind of wait it out, monitor and do things very slowly. But if you are doing it in an inpatient setting where things are, things are definitely being monitored.
47:50 Speaker 04 Everyone is watching like a hawk. You you can definitely have more grace um to increase it more rapidly than it than it sets in the three days. And and I think that's safe because of that respiratory um ceiling with the buprenorphine. So it kind of depends on the setting where you're at.
48:12 Speaker 03 One thing I love about the Butrans patch is for my nursing home patients who um aren't their pain isn't controlled by the tramadol or the hydrocodone, but they don't really need to go to a fentanyl patch or an oxycodone. You can use that Butrans patch for even an opioid naive patient at the five microgram dose, correct?
48:30 Speaker 04 Yeah, because like the if we think about if we think about the Butrans five and if we convert that to the oromorphine equivalent, it's it's a very baby low dose. And so I like it because if we think about it, um how we convert almost like a fentanyl patch. Then um because we kind of draw the similarity potency of the upper limit of Butrans of buprenorphine and fentanyl. So the way we convert fentanyl in the most, you know, traditional way. If if if we go back to how um Dr. Lynn McPherson in that Oprah conversion book, you know, we multiply
49:13 Speaker 04 that fentanyl patch dose times two and then we we we get the oromorphine equivalent. So meaning if I give you an example, like a fentanyl um twelve microgram patch, if we multiply by two, it's about twenty four or more morphine equivalent. And if we do the same calculation, even though there isn't an official way to do that for Butrans. So if we do the same math trick to Butrans, which is five multiplied by two, then it's about like what ten or more of a grilling. That's a very, very conservative dose. It's a low dose. So for that argument, I that's part of the reason why I feel like it's you. You can start it with, you know, even opioid naive patients
49:57 Speaker 04 because it's such a conservative dose.
50:00 Speaker 03 Yeah, I love that. Well, I tell you what, I have learned so much today and there's so much I still need to learn about BUP. Brett, you've given us a good overview, a good baseline to start learning more. And hopefully, you know, as we use it more and learn more, see the benefits, especially in our geriatric patients, it'll be prescribed more. Because I keep talking about it, but a lot of my providers still aren't prescribing it for our patients. And so I do think with opioid stewardship and the lower side effect profile, it will be used more. And so as pharmacists, you need to be equipped to know the overviews, the dosings, and things like that. So thank you for sharing your wealth of information. And if people want to reach you, where can they find you, Sing Ping?
50:43 Speaker 04 They can absolutely go to my LinkedIn page. You know, my name is Sing Ping Chow, and I think there's only one Sing Ping out there. And so feel free to follow my LinkedIn page. I try to share as much of the opioid tips and also patient stories. And like I say, the amount of knowledge, which is any kind of opioid dosing right now is still lacking because of the training. And so I try to really be more advocate of that opioid dosing realm, because it's so important for us to really start paying attention, not just looking at
51:25 Speaker 04 how we are going to, how we're going to address the opioid pandemic and the opioid crisis. Because right now, there's a lot of, you know, a lot of news and a lot of push to address the opioid crisis, let it be the suboxone management. But I think one of the things that is really missing out is, how are we approaching dosing opioid itself? And so with that, you know, I do try my very best to share as much experience and knowledge of that. So I hope that everyone will, you know, learn more through the stories and experience that I share online.
52:03 Speaker 03 Yes, definitely follow Sing Ping on LinkedIn and you will learn a lot. So thanks, everyone for listening. Have a great day.
Previous New Partnership Empowering Independent Pharmacy & GLP-1 Marketing | TWIRx Next Sports Pharmacy: Play Ball! | Pain Pod Page updated November 15, 2026 · transcript and summary are machine-generated